AGOURON DESIGNING ANTI-AIDS DRUGS USING IDASCA TECHNOLOGY
AGOURON DESIGNING ANTI-AIDS DRUGS USING IDASCA TECHNOLOGY under a recently announced agreement with Cambridge BioScience. According to a joint Sept. 9 press release, Agouron will have the right to commercialize AIDS drugs produced by the joint effort, while Cambridge will have rights to any vaccines and diagnostic products developed. "Cambridge will apply proprietary technology in molecular biology and protein chemistry to produce and purify genetically engineered proteins known to be essential for the viability of the AIDS virus," the release states. "Agouron will determine the distinguishing three-dimensional structure of these proteins by x-ray crystallography. With the assistance of computer-aided simulation, Agouron will then design and synthesize drug molecules engineered to inactivate the AIDS proteins and to disarm the AIDS virus." The collaboration has the support of a $4.3 mil. NIH grant. The funds were awarded to a consortium of Agouron Pharmaceuticals, Cambridge BioScience and the laboratory of Dana-Farber Cancer Institute Researcher William Haseltine, PhD. Agouron's drug design activities revolve around the IDASCA methodology, or inhibitor design by active site crystallographic analysis. According to a recent prospectus detailing the La Jolla, California-based firm's initial public offering, IDASCA facilitates rapid determination of a therapeutically important protein's three-dimensional structure and its interaction with a binding drug molecule ("The Pink Sheet" March 30, T&G-7).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth